BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21637053)

  • 1. Clinical role of FDG PET/CT for methotrexate-related malignant lymphoma.
    Minamimoto R; Ito K; Kubota K; Morooka M; Masuda-Miyata Y; Hirai R; Kitahara H; Tanimura A; Hagiwara S; Miwa A
    Clin Nucl Med; 2011 Jul; 36(7):533-7. PubMed ID: 21637053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
    Watanabe S; Manabe O; Hirata K; Oyama-Manabe N; Hattori N; Kikuchi Y; Kobayashi K; Toyonaga T; Tamaki N
    BMC Cancer; 2016 Aug; 16():635. PubMed ID: 27528380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation.
    Ikeda K; Nakamura T; Kinoshita T; Fujiwara M; Uose S; Someda H; Miyoshi T; Io K; Nagai K
    Clin J Gastroenterol; 2016 Feb; 9(1):17-21. PubMed ID: 26733461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG PET/CT in a patient with spontaneous remission of methotrexate-associated lymphoproliferative disorders after interruption of methotrexate.
    Kuramoto R; Hirata K; Takei T; Oridate N; Suzuki S; Yamada Y; Imamura M; Tamaki N
    Clin Nucl Med; 2011 Jul; 36(7):582-3. PubMed ID: 21637066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature.
    Yamashita H; Kubota K; Takahashi Y; Minamimoto R; Morooka M; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2014 Jul; 24(4):645-50. PubMed ID: 24252024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
    Newman JS; Francis IR; Kaminski MS; Wahl RL
    Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
    Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
    Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F-18 FDG PET/CT findings in two patients with pyothorax-associated lymphoma.
    Ito K; Kubota K; Morooka M; Aruga T; Mochizuki N; Itami J; Matsuda H
    Clin Nucl Med; 2010 Oct; 35(10):802-5. PubMed ID: 20838292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of conventional whole-body ¹⁸F-FDG PET/CT in the incidental findings of parotid masses.
    Wang HC; Zuo CT; Hua FC; Huang ZM; Tan HB; Zhao J; Guan YH
    Ann Nucl Med; 2010 Oct; 24(8):571-7. PubMed ID: 20640540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.
    Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T
    Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
    Manohar K; Bhattacharya A; Mittal BR
    Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.